Survival of patients with multiple myeloma has improved substantially because of availability of new therapies including autotransplants, immunomodulating drugs and proteasome-inhibitors. Second primary cancers have emerged as an important determinant of morbidity and mortality among cancer survivors. Even though there is an increased risk of new cancers of the lymphoreticular and haematopoetic system, it is very rare for Hodgkin’s lymphoma to occur as a second malignancy following autologous peripheral blood stem cell transplantation (APBSCT) for myeloma. We report a case of a female with plasma cell leukemia treated with autologous peripheral blood stem cell transplantation and lenalidamide maintenance. She developed cervical lymphadenopathy 4.5 years after the APBSCT, biopsy confirmed the diagnosis of classical Hodgkin’s lymphoma, nodular sclerosis type. Since she developed allergic reaction to ABVD, she was given 6 cycles of COPP chemotherapy and is in complete remission now.